PTK9L (N-term), 28-57 Antibody from MYBIOSOURCE INC.

Search, find, compare suppliers for anti-PTK9L (N-term), 28-57 antibody, protein, ELISA kits.

Edit 
Antigenic SpecificityPTK9L (N-term), 28-57
Clonepolyclonal
Host SpeciesRabbit
Reactive Specieshuman, mouse
Isotypen/a
Formatpeptide affinity purified
Size0.08 mL, 0.4 mL
Concentrationvial concentration: 0.33
ApplicationsWestern Blot (WB), ELISA (EIA), Immunohistochemistry (IHC), Flow Cytometry (FC/FACS)
Reviews / RatingsIf you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY.
DescriptionThis PTK9L antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 28-57 amino acids from the N-terminal region of human PTK9L. The protein encoded by this gene was identified by itsinteraction with the catalytic domain of protein kinase C-zeta. Theencoded protein contains an actin-binding site and an ATP-bindingsite. It is most closely related to twinfilin (PTK9), a conservedactin monomer-binding protein.
Immunogenn/a
Other Names[Twinfilin-2; A6-related protein; hA6RP; Protein tyrosine kinase 9-like; Twinfilin-1-like protein; TWF2; PTK9L]
Gene, Accession #[TWF2], Gene ID: 11344, NCBI: NP_009215.1, UniProt: Q6IBS0
Catalog #MBS9212213
Price$165, $370
Order / More InfoPTK9L (N-term), 28-57 Antibody from MYBIOSOURCE INC.
Product Specific ReferencesBailey, S.D., et al. Diabetes Care 33(10):2250-2253(2010) Han, S., et al. Hum. Immunol. 71(7):727-730(2010) Rajaraman, P., et al. Cancer Epidemiol. Biomarkers Prev. 19(5):1356-1361(2010) Talmud, P.J., et al. Am. J. Hum. Genet. 85(5):628-642(2009) Rajaraman, P., et al. Cancer Epidemiol. Biomarkers Prev. 18(5):1651-1658(2009)
MYBIOSOURCE INC.
MYBIOSOURCE INC.
MYBIOSOURCE INC.
P.O. Box 153308
San Diego CA 92195-3308
P: 1.858.633.0165
P: 1.888.MBS.0165 (1.888.627.0165) (US & Canada)
F: 1.858.633.0166

sales@mybiosource.com

http://www.MyBioSource.com

Profile of MYBIOSOURCE INC.
Return to Antibodies

© 1980 - 2024 Linscott's Directory, Linscott's USA. All rights reserved.